Universitaetsklinikum Erlangen AöR

The clinical research here is centered on neoplasms, with studies focused on cancer and large B-cell lymphoma. These trials are designed to explore new treatment options and assess how well emerging therapies perform in people with blood-related cancers.

• Evaluating new treatment strategies for large B-cell lymphoma
• Comparing the effectiveness of combination approaches in cancer care
• Assessing safety and tolerability of oncology treatments

With 5 trials and 81 investigators contributing, Medizinische Klinik 5 supports focused research aimed at improving outcomes for patients with difficult-to-treat malignancies.

The site is also active in studies of blood cancers, especially large B-cell lymphoma, where researchers are testing whether new combinations can improve disease control and extend the time before the disease worsens.

• Testing combination therapy for newly diagnosed large B-cell lymphoma
• Measuring treatment effectiveness through progression-free survival
• Supporting development of more effective lymphoma therapies

This work reflects a strong clinical focus on refining care for patients with aggressive hematologic malignancies.

Another part of the research portfolio involves follow-up studies that look at whether ongoing treatment remains safe and appropriate for patients who have already received therapy in other studies.

• Continuing darolutamide treatment in eligible participants
• Monitoring treatment safety over time
• Supporting long-term care decisions in oncology

At Universitaetsklinikum Erlangen AöR, these studies help build a clearer picture of how cancer treatments perform beyond initial use, with attention to both benefit and safety.